AKT3 and breast cancer: Reduced MIR497HG expression resulted in increased levels of miR‐497/195 target genes (AKT3, BCL2, MAP2K1, RAF1, and CCND1), which activated the of PI3K‐AKT signaling and, as a result, increased ERα transcriptional activity, inducing tamoxifen resistance.[37] Inhibiting the AKT signaling pathway decreased ERα transcriptional activity to sensitize MIR497HG‐depleted breast cancer cells to tamoxifen treatment.